Literature DB >> 2260856

Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration.

K Sakai1, D J Mitchell, T Tsukamoto, L Steinman.   

Abstract

We isolated a complementary DNA clone encoding a 52-kd protein recognized by an anti-neuronal cell antibody in serum from a patient with paraneoplastic cerebellar degeneration associated with uterine carcinoma. The recombinant protein expressed in prokaryotic cells was specifically recognized by the anti-neuronal cell antibody from the patient, and its molecular weight was identical to that of antigenic proteins in the cerebellum. The deduced protein consisted of 450 amino acids dominated by hydrophilic residues, the calculated relative molecular mass was 51,238, and the predicted value of the isoelectric point was 4.99. This complementary DNA sequence and the deduced protein sequence have not been reported previously, and the sequences showed no homologies with the complimentary DNA or the amino acid sequences in the GenBank, EMBL, or NBRF databases, including the complementary DNA for a 34-kd cerebellar protein (CDR34) that is recognized by an anti-Purkinje cell antibody. Unexpectedly, the transcript of this gene was detected not only in the cerebellum and the brain stem but also in an extraneural tissue, the intestine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2260856     DOI: 10.1002/ana.410280515

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1992-11-25       Impact factor: 16.971

2.  Pursuing an occult carcinoma in a patient with subacute cerebellar degeneration and anticerebellar antibodies. Need for vigorous follow-up.

Authors:  J E Greenlee; H R Brashear; K A Jaeckle; A Geleris; K Jordan
Journal:  West J Med       Date:  1992-02

3.  Long term course of change in anti-Yo antibody content in paraneoplastic cerebellar degeneration.

Authors:  K Tanaka; M Tanaka; S Igarashi; O Onodera; T Nakajima; M Yamazaki; T Miyatake; S Tsuji
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

4.  Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration.

Authors:  H Fathallah-Shaykh; S Wolf; E Wong; J B Posner; H M Furneaux
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

5.  The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival.

Authors:  H J Okano; W Y Park; J P Corradi; R B Darnell
Journal:  Genes Dev       Date:  1999-08-15       Impact factor: 11.361

Review 6.  Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain.

Authors:  R B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

7.  The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells.

Authors:  Kevin J O'Donovan; Jennifer Diedler; Graeme C Couture; John J Fak; Robert B Darnell
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

8.  Paraneoplastic cerebellar degeneration with a circulating antibody against neurons and non-neuronal cells.

Authors:  H Tomimoto; J M Brengman; T Yanagihara
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies.

Authors:  H Imai; R L Ochs; K Kiyosawa; S Furuta; R M Nakamura; E M Tan
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

Review 10.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.